Pharmacology, Toxicology and Pharmaceutical Science
Psoriatic Arthritis
100%
Psoriasis
32%
Disease
19%
Disease Activity
18%
Disease Modifying Antirheumatic Drug
11%
Placebo
10%
Clinical Trial
9%
Cohort Study
7%
Randomized Controlled Trial
7%
Tumor Necrosis Factor Inhibitor
7%
Biological Product
6%
Arthritis
6%
Guselkumab
6%
Bimekizumab
5%
Upadacitinib
5%
Medicine and Dentistry
Psoriatic Arthritis
77%
Psoriasis
30%
Disease Activity
16%
Disease
11%
Quality of Life
9%
Disease Modifying Antirheumatic Drug
7%
Patient-Reported Outcome
6%
Rheumatology
6%
Primary Health Care
6%
Clinical Trial
5%
Biological Product
5%
Randomized Controlled Trial
5%
Musculoskeletal Disease
5%
Arthritis
5%
Nursing and Health Professions
Psoriatic Arthritis
47%
Psoriasis
11%
Disease
9%
Disease Activity
8%
Systematic Review
6%
Quality of Life
6%
Primary Medical Care
6%
Clinical Practice
5%
Patient-Reported Outcome
5%
